4D Molecular Therapeutics (FDMT) Long-Term Investments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has 6 years of Long-Term Investments data on file, last reported at $66.7 million in Q1 2026.

• On a quarterly basis, Long-Term Investments fell 51.29% year-over-year to $66.7 million in Q1 2026; TTM through Mar 2026 was $66.7 million, a 51.29% decrease from a year earlier, with the FY2025 full-year figure at $111.4 million, up 38.22% from the prior year.
• Long-Term Investments for Q1 2026 stood at $66.7 million, down from $111.4 million in the prior quarter.
• Over the last five years, Long-Term Investments for FDMT reached as high as $137.0 million in Q1 2025 and fell as low as $1.4 million in Q1 2023.
• Historically, Long-Term Investments has averaged $55.4 million across 5 years, with a median of $48.8 million in 2024.
• Across the five-year window, Long-Term Investments slumped 97.09% in 2023 and jumped 4379.86% in 2024, its largest moves.
• Year by year, Long-Term Investments stood at $4.9 million in 2022, then surged by 123.19% to $11.0 million in 2023, then soared by 635.65% to $80.6 million in 2024, then soared by 38.22% to $111.4 million in 2025, then sank by 40.08% to $66.7 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $66.7 million in Q1 2026, $111.4 million in Q4 2025, and $67.2 million in Q3 2025.